Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 29;8(5):1374.
doi: 10.4022/jafib.1374. eCollection 2016 Feb-Mar.

The Cost Effectiveness of LAA Exclusion

Bahij Kreidieh  1 , Moisés Rodríguez Mañero  1 , Sergio H Ibarra Cortez  1 , Paul Schurmann  1 , Miguel Valderrábano  1
Affiliations
Review

The Cost Effectiveness of LAA Exclusion

Bahij Kreidieh et al. J Atr Fibrillation. .

Abstract

Left atrial appendage (LAA) exclusion strategies are increasingly utilized for stroke prevention in lieu of oral anticoagulants. Reductions in bleeding risk and long-term compliance issues bundled with comparable stroke prevention benefits have made these interventions increasingly attractive. Unfortunately, healthcare funding remains limited. Comparative cost economic analyses are therefore critical in optimizing resource allocation. In this review we seek to discourse the cost economics analysis of LAA exclusion over available therapeutic alternatives (warfarin and the new oral anticoagulants (NOACs)). .

Keywords: Cost Effectiveness; Left Atrial Appendage Exclusion; Watchman,Lariat.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Relative impact of available stroke prevention interventions on life expectancy and quality adjusted life years in patients with NVAF as derived from Singh et al, 2013
Figure 2.
Figure 2.. Relative discounted lifetime costs associated with various stroke prevention interventions in patients with NVAF as derived from Singh et al, 2013
Figure 3.
Figure 3.. Total cumulative cost of LAA occlusion vs Warfarin at year 1 and year 10. Cost of LAA occlusion is significantly higher initially, but costs level off at 10 years post-intervention
See this image and copyright information in PMC

References

    1. Solomon Matthew D, Ullal Aditya J, Hoang Donald D, Freeman James V, Heidenreich Paul, Turakhia Mintu P. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012 Feb;13 (2):86–96. - PubMed
    1. Holmes David R, Kar Saibal, Price Matthew J, Whisenant Brian, Sievert Horst, Doshi Shephal K, Huber Kenneth, Reddy Vivek Y. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol. 2014 Jul 8;64 (1):1–12. - PubMed
    1. Lee Won Chan, Lamas Gervasio A, Balu Sanjeev, Spalding James, Wang Qin, Pashos Chris L. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11 (2):281–98. - PubMed
    1. Kim Michael H, Johnston Stephen S, Chu Bong-Chul, Dalal Mehul R, Schulman Kathy L. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011 May;4 (3):313–20. - PubMed
    1. Lloyd-Jones Donald M, Wang Thomas J, Leip Eric P, Larson Martin G, Levy Daniel, Vasan Ramachandran S, D'Agostino Ralph B, Massaro Joseph M, Beiser Alexa, Wolf Philip A, Benjamin Emelia J. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004 Aug 31;110 (9):1042–6. - PubMed

LinkOut - more resources